The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-30

Study Completion Date

2021-08-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Niacin Therapy on Lipoprotein Composition and Function

NCT02322203

Cardiovascular Disease

COMPLETED NA

Nicotinamide Riboside and Metabolic Health

NCT02835664

Obesity Insulin Resistance

COMPLETED NA

Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease

NCT01391377

Peripheral Arterial Disease

TERMINATED NA

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

NCT03501433

Aging Lipemia

COMPLETED NA

Antioxidant Functions of Lipoic Acid

NCT00065624

Hypercholesterolemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Niagen is a patented formula which is the first and only commercially available form of Nicotinamide Riboside (NR). It has been proven in basic science studies as a highly effective NAD booster, but it also works as a vitamin B3 supplement. NAD helps pass energy from glucose to other pathways in the cell. Niagen (Nicotinamide Riboside, vitamin B3) is one of the most effective NAD+ precursors to support cellular health.

The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment NAD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy control

Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.

Group Type ACTIVE_COMPARATOR